Pfizer Inc. (PFE)
| Market Cap | 146.35B |
| Revenue (ttm) | 62.79B |
| Net Income (ttm) | 9.83B |
| Shares Out | 5.69B |
| EPS (ttm) | 1.73 |
| PE Ratio | 14.96 |
| Forward PE | 8.61 |
| Dividend | $1.72 (6.68%) |
| Ex-Dividend Date | Nov 7, 2025 |
| Volume | 22,624,741 |
| Open | 25.85 |
| Previous Close | 25.71 |
| Day's Range | 25.66 - 25.86 |
| 52-Week Range | 20.92 - 27.69 |
| Beta | 0.42 |
| Analysts | Buy |
| Price Target | 28.56 (+10.96%) |
| Earnings Date | Nov 4, 2025 |
About PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for PFE stock is "Buy." The 12-month stock price target is $28.56, which is an increase of 10.96% from the latest price.
News
This 7% Yielder Could Be a Top AI Play
A looming patent cliff in which Pfizer will lose patent exclusivity to a handful of drugs has combined with cratering revenue from COVID-19 treatments to drive Pfizer shares down 50% since 2022. Pfize...
3 Stocks to Buy and Hold: the Long-Term Play for Your Portfolio
Intuitive Surgical shows why now is a good time to consider buying surgical-robot competitor Medtronic. Eli Lilly helps explain why down-and-out drugmaker Pfizer could be worth a close look for long-t...
Pfizer: The Patent Cloud Is An Opportunity For Bargain Hunters
Pfizer remains a compelling bargain, supported by a strong dividend yield and undervalued financial metrics, despite post-pandemic headwinds. PFE's acquisition of Metsera positions it for growth in th...
Pfizer, Mastercard Among 24 Companies To Announce Annual Increases In December
This is my latest article, where I provide predictions of upcoming dividend increases from companies with long-term dividend growth histories. Most of the dividend increases announced in the last two ...
8 'Safer' Dividend Buys In Barron's 23 Better November Bets Than T-Bills
Eight of the top fifteen Barron's Better Bets (BBB) 'Safer' dividend stocks, including Conagra, Altria, and Verizon, are currently attractively priced for income investors. Analyst forecasts project n...
Have $2,000 to Invest? Here Are 4 of My Favorite Dividend Stocks for the Next 5 Years
Pfizer and Johnson & Johnson are healthcare leaders and faithful dividend payers. Home Depot is facing a difficult operating environment, but its core business remains strong.
Final Trade: DAL, AXP, PFE, HMY
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings
Valneva SE (NASDAQ: VALN) shared final immunogenicity and safety data on Wednesday from the Phase 2 study, VLA15-221, of the Lyme disease vaccine candidate, VLA15.
Did Pfizer Just Say "Checkmate" to Novo Nordisk?
Pfizer has been trying to get in on the billion-dollar weight loss drug market. Novo Nordisk initially dominated this market but has been losing ground to Eli Lilly.
Is This the Best Value Stock to Buy While Markets Are Volatile?
Pfizer possesses several qualities that make it attractive when market volatility is high. The stock has a low forward earnings multiple and a higher -- yet still attractive -- EV-to-EBITDA ratio.
Want Over $7,000 in Annual Dividends? Invest $25,000 in Each of These 4 Stocks.
Income investors have been forced to seek yield in new places as stocks bump up against all-time highs. This diversified basket of blue chip names currently delivers over 7% annual yield.
JNJ Stock vs. PFE Stock: Which Pharmaceutical Giant Is A Better Buy?
The pharmaceutical powerhouse Johnson & Johnson (NYSE: JNJ) has significantly outperformed its competitor Pfizer (NYSE: PFE) this year. JNJ's stock has risen by almost 45%, whereas PFE has declined by...
2 Healthcare Stocks for Beginner Investors With a 20-Year Time Horizon
If you want to invest in top healthcare stocks, both of these are worth consideration. Pfizer is moving past the pandemic era, and tremendous growth could be ahead.
U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer
NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the U.S. Food and Drug Administration...
This 7%-Yielding Dividend Stock Is About to Enter an Exciting New Phase
Pfizer is pursuing a potentially lucrative area of the vast oncology market. The drugmaker is also targeting the fast-growing weight loss space.
Pfizer Crosses Below Key Moving Average Level
In trading on Thursday, shares of Pfizer crossed below their 200 day moving average of $24.58, changing hands as low as $24.28 per share. Pfizer shares are currently trading off about 1.6% on the day.
$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield
Screening large-cap Health Care names using earnings yield plus ROTC identified five undervalued blue-chip stocks over $100B market cap. Merck, Bristol-Myers, Gilead, Pfizer, and Amgen screen as the c...
Is Pfizer's 6.9%-Yielding Dividend Still Safe?
A high-yielding payout hasn't been enough reason for investors to buy Pfizer's stock. The pharmaceutical giant's valuation has been cut in half in just three years.
October Readers Identified 10 Ideal "Safer" Dividends In 39 Dogs
This article highlights the October 2025 ReFa/Ro Dogs, focusing on high-yield, low-priced dividend stocks for contrarian income investors. Top projected net gainers include MFA, CIM, HAFN, IPG, and LY...
Pfizer: Is This Pharma Giant Finally A Bargain
Following Pfizer's victory over Novo Nordisk in the "war" for Metsera, its stock resumed its upward momentum. But before the deal was completed, it again beat Wall Street analysts' consensus EPS and r...
Pfizer in $41.5 million settlement with Texas over ADHD drug
Pfizer and supplier Tris Pharma reached a $41.5 million settlement with Texas to resolve claims over alleged quality control lapses in medicine to treat attention deficit hyperactivity disorder in chi...
Pfizer Inc. (PFE) Presents at Jefferies London Healthcare Conference 2025 Transcript
Pfizer Inc. ( PFE) Jefferies London Healthcare Conference 2025 November 19, 2025 4:00 AM EST Company Participants David Denton - Executive VP & CFO Conference Call Participants Akash Tewari - Jefferi...
